Compare Vital Farms Inc (VITL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vital Farms Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Vital Farms Inc trades at $9.33 (market cap $405.27M), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 24.9× Vital Farms Inc's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vital Farms Inc for 14 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| VITL | XBI | |
|---|---|---|
Market Cap | $405.27M | $10.11B |
Volume | 1,810,837 | 12,903,266 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $43.68 | $169.55 |
52-Week Low | $8.28 | $104.99 |
Typical Hold Time | 14 Days | 38 Days |
Enterprise Value | $492.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vital Farms (VITL) trades at $9.435, up 2.11% today, amid a challenging period marked by volatile earnings and a bearish technical signal. The stock shows weak profitability with a net income margin of 0.02% in 2026, though valuation ratios like P/S of 0.55 appear attractive. Recent news highlights strategic review for a potential sale, with price targets ranging from $10 to $20. Cash flow remains negative, driven by heavy investing activities, while institutional interest persists with new acquisitions.
The outlook is mixed: analyst consensus is bullish with a $13.11 target, but near-term risks include pricing pressure in the egg market and earnings volatility. Recovery hinges on stabilizing supply costs and executing strategic options. Investors should weigh low valuation against operational challenges and industry headwinds for potential upside.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
